1,158 reports of this reaction
3.9% of all AMIODARONE HYDROCHLORIDE reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for AMIODARONE HYDROCHLORIDE, manufactured by Upsher-Smith Laboratories, LLC. There are 1,158 FDA adverse event reports linking AMIODARONE HYDROCHLORIDE to DYSPNOEA. This represents approximately 3.9% of all 29,334 adverse event reports for this drug.
Patients taking AMIODARONE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among AMIODARONE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for AMIODARONE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,158 FDA reports for AMIODARONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.9% of all adverse event reports for AMIODARONE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking AMIODARONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.